Navigation Links
Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Date:2/3/2016

SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference in New York City.

The live presentation takes place on Wednesday, February 10 at 11:55am ET (8:55am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
2. Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
3. Neurocrine Biosciences to Present at Credit Suisses 24th Annual Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
5. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
6. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
7. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
8. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
9. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
10. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
11. Neurocrine Biosciences Reports Second Quarter 2015 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... , ... James M. Barthel, CEO of MT2 Firing Range Services said, “MT2 ... lead into profit by giving the range owner/manager the highest value for their reclaimed ... highest value for their lead. No one reclaims more lead or pays more for ...
(Date:11/5/2019)... MONTCLAIR, N.J. (PRWEB) , ... November 05, 2019 ... ... San Antonio, 555 South Alamo Street in Texas will be a timely program ... instruction in the management of chronic pain. , The Texas Medical Board requires ...
(Date:11/5/2019)... ... November 05, 2019 , ... Ida Culver House Broadview announced today ... will result in the layoff of 147 full- and part-time workers, and 53 current ... will enable Ida Culver House Broadview to shift its care model to provide higher ...
Breaking Medicine Technology:
(Date:11/6/2019)... ... November 06, 2019 , ... Founder of the Trivedi Effect®, ... God of their understanding, as well as, to illuminate the path of awareness ... fate, and fortune. , The next Trivedi Effect® Online Workshop is scheduled ...
(Date:11/6/2019)... Va. (PRWEB) , ... November 06, 2019 , ... ... Thinking Skills and Innovative Techniques , to Improve Inspections, An FDAnews Workshop, Nov. ... Cause Analysis CAPA Investigations starts in one week. , Dear FDA-Regulated Executive, , ...
(Date:11/6/2019)... Germany (PRWEB) , ... November ... ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... and Chief Executive Officer, John Chiminski, has received the inaugural CPhI Pharma ...
(Date:11/5/2019)... SEATTLE (PRWEB) , ... November 05, 2019 , ... ... informed care strategies, announces Associate Managing Editor, Sabitha Rajan, MD, MSc, will be a ... Conference + Expo on Nov. 12, 2019, at 9:00 a.m., in Austin, Texas. ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... by PhillyCooke Consulting and FDAnews, Dec. 10-11, 2019 , Hilton Cabana Miami Beach ... World-Class Advertising and Promotion Review Program ends on Nov. 12. , Current ...
Breaking Medicine News(10 mins):